Browse Research Peptides

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a crucial role in tissue repair, cell migration, and blood vessel formation in the body.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels.

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) with a Drug Affinity Complex that extends its half-life significantly compared to native GHRH.

Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.

GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been extensively studied for wound healing, skin rejuvenation, and tissue remodeling.

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the incretin hormone GLP-1, regulating blood glucose levels, appetite, and body weight through multiple metabolic pathways.

Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research.

Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the most profound metabolic effects seen in obesity research to date.

Orforglipron is an oral non-peptide GLP-1 receptor agonist developed by Eli Lilly, representing a breakthrough in weight management and type 2 diabetes treatment by enabling once-daily oral dosing of a small molecule that mimics incretin hormone activity.

Survodutide is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, investigated for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk, designed for once-weekly subcutaneous administration and studied both as monotherapy and in combination with semaglutide (CagriSema) for obesity and type 2 diabetes management.

Selank is a synthetic peptide analog of the endogenous tetrapeptide tuftsin. It was developed in Russia for its anxiolytic and nootropic properties and has been studied for effects on stress response and cognitive function.

GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. It was one of the first growth hormone releasing peptides developed.

GHRP-2 is a synthetic growth hormone secretagogue that stimulates GH release through the ghrelin receptor. It is considered one of the most potent GHRPs for GH stimulation.

Hexarelin is a synthetic growth hormone secretagogue and one of the most potent GHRPs. It has been studied for cardioprotective effects in addition to GH release properties.

Sermorelin is a synthetic analog of growth hormone releasing hormone (GHRH) containing the first 29 amino acids, which represent the active portion of the natural hormone.

PT-141 (Bremelanotide) is a synthetic peptide that acts on melanocortin receptors. It was developed from the tanning peptide Melanotan II and has been studied for sexual dysfunction.

Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone. It was developed for research into tanning, sexual function, and appetite regulation.

Epithalon is a synthetic tetrapeptide based on the natural peptide Epithalamin produced by the pineal gland. It has been studied for effects on telomerase activity and longevity.

LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in innate immunity. It has broad-spectrum antimicrobial activity and immunomodulatory properties.

Thymosin Alpha-1 is a peptide originally isolated from thymic tissue that modulates immune function. It is approved in several countries for immune deficiency conditions and as an adjuvant therapy.

DSIP is a neuropeptide that was originally isolated from rabbit brain during slow-wave sleep. It has been studied for effects on sleep, stress response, and hormonal regulation.

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that has been studied for its effects on fat metabolism without the growth-promoting effects of full GH.

Tesamorelin is a synthetic growth hormone releasing hormone analog. It is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.

SNAP-8 is a synthetic peptide designed to reduce wrinkles by modulating neuromuscular junction activity. It is an extension of the hexapeptide Argireline.

FOXO4-DRI is a senolytic peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 interaction.

MOTS-c is a mitochondria-derived peptide that plays a role in metabolic homeostasis. It is encoded in the mitochondrial genome and affects insulin sensitivity and cellular metabolism.

Kisspeptin is a neuropeptide that plays a central role in regulating the reproductive hormone axis. It is the endogenous ligand for the GPR54 receptor.

TB4-FRAG (Ac-SDKP) is a tetrapeptide fragment of Thymosin Beta-4. It has been studied for anti-fibrotic and cardioprotective effects.

Liraglutide is a GLP-1 receptor agonist with 97% amino acid sequence homology to native GLP-1, modified with a palmitic acid chain for extended duration of action, used in research for diabetes and obesity.

Teduglutide is a GLP-2 (glucagon-like peptide-2) analog that promotes intestinal mucosal growth and function, FDA-approved for short bowel syndrome research and treatment.

KPV is a naturally-occurring tripeptide derived from the C-terminus of alpha-melanocyte stimulating hormone (α-MSH), demonstrating potent anti-inflammatory effects independent of melanocortin receptor activation.

Mazdutide is a dual GLP-1 and glucagon receptor agonist based on an oxyntomodulin analog, developed by Innovent Biologics in partnership with Eli Lilly, and the first drug of its class to receive regulatory acceptance for obesity in China.

Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors.

Follistatin 344 is a naturally occurring glycoprotein that functions as a potent inhibitor of myostatin, activin, and other members of the TGF-beta superfamily. It has been extensively studied for its role in promoting skeletal muscle growth and as a gene therapy candidate for muscular dystrophy.

IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension, designed to have reduced binding to IGF-binding proteins and an extended biological half-life.

Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells that plays a central role in T-cell differentiation, immune regulation, and the neuroendocrine-immune axis.

Oxytocin is a cyclic nonapeptide neurohormone produced in the hypothalamus and released by the posterior pituitary, playing critical roles in social bonding, maternal behavior, and neuromodulation of emotional and cognitive processes.

Pramlintide is a synthetic analog of the pancreatic hormone amylin, FDA-approved as adjunctive therapy to mealtime insulin for type 1 and type 2 diabetes to improve postprandial glucose control and promote satiety.